{"version":"1.0","provider_name":"The Medical Xchange","provider_url":"https:\/\/themedicalxchange.com\/en\/","title":"New Data in Metastatic Castration-resistant Prostate Cancer - The Medical Xchange","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"rCOM0Ue0Ck\"><a href=\"https:\/\/themedicalxchange.com\/en\/review\/39th-european-society-of-medical-oncology-esmo-con\/\">New Data in Metastatic Castration-resistant Prostate Cancer<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/themedicalxchange.com\/en\/review\/39th-european-society-of-medical-oncology-esmo-con\/embed\/#?secret=rCOM0Ue0Ck\" width=\"600\" height=\"338\" title=\"&#8220;New Data in Metastatic Castration-resistant Prostate Cancer&#8221; &#8212; The Medical Xchange\" data-secret=\"rCOM0Ue0Ck\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/themedicalxchange.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/themedicalxchange.com\/wp-content\/uploads\/2014\/10\/3005_ESMO_2014_EN_Fig_1.PNG","thumbnail_width":960,"thumbnail_height":720,"description":"Madrid - The introduction of new therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) is altering strategies for prolonged disease control. New data presented on several of these options at the 2014 European Society for Medical Oncology (ESMO) Congress are relevant to the effort to define how mCRPC treatment is best sequenced. The most significant data were generated from two phase III trials. In one, the latest long-term survival outcomes were made available from the COU-AA-302 trial with abiraterone acetate. In the other, quality of life outcomes were evaluated in the PREVAIL study of enzalutamide. Phase II efficacy and safety data were presented on sipuleucel-T and sorafenib. In addition, a series of studies evaluating prognostic factors and biomarkers provided context for the ongoing effort to determine which treatments should be used in the first-, second- and third-line settings."}